Roche/Arrowhead was the largest of Alnylam Pharmaceuticals, Inc.’s 5 reported lines in fiscal 2012, at $37.32M — 56% of $66.73M.
| Collaborator | FY 2012 |
|---|---|
| Roche/Arrowhead | $37.32M |
| Takeda | $21.97M |
| Cubist | $2.78M |
| Other | $2.70M |
| Monsanto | $1.95M |
| Total | $66.73M |
In fiscal 2012, which ended December 31, 2012, the 5 revenue lines Alnylam Pharmaceuticals, Inc. reported in this breakdown added up to $66.73M. Roche/Arrowhead was the largest revenue line, at $37.32M or 55.9% of the total, followed by Takeda ($21.97M, 32.9%) and Cubist ($2.78M, 4.2%). Together, the two largest revenue lines made up 88.9% of this total.
This breakdown covers every fiscal year from 2012 to 2012, as reported in Alnylam Pharmaceuticals, Inc.'s annual filings.
Roche/Arrowhead was the largest of Alnylam Pharmaceuticals, Inc.’s 4 reported lines in fiscal 2011, at $55.98M — 68% of $82.76M.
| Research Collaborator | FY 2010 | FY 2011 |
|---|---|---|
| Roche/Arrowhead | $55.98M | $55.98M |
| Takeda | $22.25M | $22.25M |
| Novartis | $9.31M | — |
| Government Contract | $4.34M | — |
| Other | $5.80M | $2.06M |
| Cubist | $2.36M | $2.47M |
| Total | $100.04M | $82.76M |
In fiscal 2011, which ended December 31, 2011, the 4 revenue lines Alnylam Pharmaceuticals, Inc. reported in this breakdown added up to $82.76M. The revenue lines reported changed from fiscal 2010, so the total is not directly comparable with the $100.04M reported that year. Roche/Arrowhead was the largest revenue line, at $55.98M or 67.6% of the total, followed by Takeda ($22.25M, 26.9%) and Cubist ($2.47M, 3.0%). Together, the two largest revenue lines made up 94.5% of this total.
Compared with fiscal 2010, Cubist grew the fastest, rising 4.4% to $2.47M. Other fell the most, down 64.4% to $2.06M. Because revenue lines were added or dropped between the two years, part of this reflects how Alnylam Pharmaceuticals, Inc. regrouped its reporting.
The table also keeps 2 revenue lines that Alnylam Pharmaceuticals, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2010 to 2011, as reported in Alnylam Pharmaceuticals, Inc.'s annual filings.
Alnylam Pharmaceuticals, Inc. (ALNY) breaks its revenue down by revenue line. In fiscal 2012, its largest revenue line was Roche/Arrowhead, with $37.32M or 55.9% of the total, followed by Takeda at $21.97M (32.9%).
Roche/Arrowhead was Alnylam Pharmaceuticals, Inc.'s largest revenue line in fiscal 2012, with $37.32M in revenue, 55.9% of the $66.73M reported across its 5 revenue lines.
Every figure is taken from Alnylam Pharmaceuticals, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2012 to 2012. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.